Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

2(50.0%)

Phase 1

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 3(2)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT01275248Phase 2Terminated

Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

Role: lead

NCT00380081Phase 3Completed

A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia

Role: lead

NCT00466193Phase 3Completed

A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia

Role: lead

NCT01106859Phase 1Completed

Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet

Role: lead

All 4 trials loaded